Analytical strategies to detect enobosarm administration in bovines

References

• Aikawa K, Miyawaki T, Hitaka T, Imai Y, Hara T, Miyazaki J, Yamaoka M, Kusaka M, Kanzaki N, Tasaka A, et al. 2015. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. Bioorg Med Chem. 23:2568–2578.
   PubMed Web of Science ®Google Scholar
• Beucher L, Dervilly-Pinel G, Cesbron N, Penot M, Gicquiau A, Monteau F, Le Bizec B. 2016. Specific characterization of non-steroidal selective androgen receptor modulators using supercritical fluid chromatography coupled to ion-mobility mass spectrometry: application to the detection of enobosarm in bovine urine. Drug Test Anal.doi:10.1002/dta.1951
   PubMed Web of Science ®Google Scholar
• Beucher L, Dervilly-Pinel G, Prévost S, Monteau F, Le Bizec B. 2015. Determination of a large set of β-adrenergic agonists in animal matrices based on ion mobility and mass separations. Anal Chem. 87:9234–9242.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Jasuja R. 2009. Selective androgen receptor modulators (SARMs) as function promoting therapies. Curr Opin Clin Nutr Metab Care. 12:232–240.
   PubMed Web of Science ®Google Scholar
• Boyle GW, Mc Killops D, Phillips PJ, Harding JR, Pickford R, Mc Cormick AD. 1993. Metabolism of casodex in laboratory animals. Xenobiotica. 23:781–798.
   PubMed Web of Science ®Google Scholar
• Canadian Sport Sanction Registry. Available from: http://cces.ca/canadian-sport-sanction-registry
   Google Scholar
• Cawley AT, Smart C, Greer C, Liu Lau M, Keledjian J. 2016. Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample. Drug Test Anal. 8:257–261.
   PubMed Web of Science ®Google Scholar
• Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. 2016. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials). Curr Oncol Rep. 18:37.
   PubMed Web of Science ®Google Scholar
• Council Directive 77/146/EEC of 7 March 1988 prohibiting the use in livestock farming of certain substances having a hormonal action. 1988. OJL. 70:16–18.
   Google Scholar
• Council Directive 96/23/EC of 29 April 1996 on measures to monitor certain substances and residues thereof in live animals and animal products and repealing. 1996. OJL. 125:10–32.
   Google Scholar
• Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. 2011. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2:153–161.
   PubMed Web of Science ®Google Scholar
• Dalton JT, Gao W. 2010a. Androgen receptor. In: Bunce CM, Campbell MJ, editors. Nuclear receptors: current concepts and future challenges. Proteins and cell regulation. Vol. 8. Birmingham (UK): Springer Editions; p. 458.
   Google Scholar
• Dalton JT, Miller DD, Kearbey JD. 2010b. SARMs and method of use thereof. US 20100249228 A1. United States Patent Application Publication, 75 pp.
   Google Scholar
• Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. 1998. Discovery of nonsteroidal androgens. Biomed Biophysical Res Communications. 244:1–4.
   PubMed Web of Science ®Google Scholar
• de Rijke E, Essers ML, Rijk JCW, Thevis M, Bovee TFH, van Ginkel LA, Sterk SS. 2013. Selective androgen receptor modulators: in vitro and in vivo metabolism and analysis. Food Addit Contam Part A. 30:1517–1526.
   PubMed Web of Science ®Google Scholar
• Dervilly-Pinel G, Courant F, Chereau S, Royer A-L, Boyard-Kieken F, Antignac J-P, Monteau F, Le Bizec B. 2012. Metabolomics in food analysis: application to control of forbidden substances. Drug Test Anal. 4:59–69.
   PubMed Web of Science ®Google Scholar
• Dervilly-Pinel G, Chereau S, Cesbron N, Monteau F, Le Bizec B. 2015. LC-HRMS based metabolomics screening model to detect various β-agonists treatments in bovines. Metabolomics. 11:403–411.
   Google Scholar
• Gao W. 2010. Androgen receptor as a therapeutic target. Adv Drug Deliv Rev. 62:1277–1284.
   PubMed Web of Science ®Google Scholar
• Gao W, Kim J, Dalton JT. 2006. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res. 23:1641–1658.
   PubMed Web of Science ®Google Scholar
• Grata E, Perrenoud L, Saugy M, Baume N. 2011. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 213:104–108.
   PubMed Web of Science ®Google Scholar
• Hansson A, Knych H, Stanley S, Thevis M, Bondesson U, Hedeland M. 2015. Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes. Drug Test Anal. 7:673–683.
   Web of Science ®Google Scholar
• Kim J, Wang R, Veverka A, Dalton T. 2013. Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropionamide] in rats. Xenobiotica. 43:993–1009.
   PubMed Web of Science ®Google Scholar
• Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT. 2005. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther. 315:230–239.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile M, Rossi Fanelli F, Muscaritoli M. 2016. Novel therapeutic options for cachexia and sarcopenia. Expert Opin Biol Ther. 16:1239–1244.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. 2008. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 6:1–26.
   Google Scholar
• Perera MA, Yin D, Wu D, Chan KK, Miller DD, Dalton J. 2006. In vivo metabolism and final disposition of a novel nonsteroidial androgen in rats and dogs. Drug Metab Dispos. 34:1713–1721.
   PubMed Web of Science ®Google Scholar
• Rojas D, Dervilly-Pinel G, Cesbron N, Penot M, Sydor A, Prévost S, Le Bizec B. 2016. Selective Androgen Receptor Modulators: comparative excretion study of Bicalutamide in bovine urine and faeces. Drug Test Anal. doi:10.1002/dta.2113. [Epub ahead of print].
   Google Scholar
• Starvecic B, Ahrens BD, Butch AW. 2013. Detection of the selective androgen receptor modulator S-4) (Andarine) in a doping control sample. Drug Test Anal. 5:377–379.
   PubMed Web of Science ®Google Scholar
• Thevis M, Thomas A, Möller I, Geyer H, Dalton JT, Schänzer W. 2011. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Commun Mass Spectrom. 25:2187–2195.
   PubMed Web of Science ®Google Scholar
• Thevis M, Kuuranne T, Walpurgis K, Geyer H, Schänzer W. 2016. Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal. 8:7–29.
   PubMed Web of Science ®Google Scholar
• Yi P, Rehmel JF, Cassidy K, Hadden C, Campanale K, Patel N, Johnson J. 2012. Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans. Drug Metab Dispos. 40:2354–2364.
   PubMed Web of Science ®Google Scholar